Trade RIT Capital Partners PLC - RCP
RIT Capital Partners PLC (RCP), formerly known as Rothschild Investment Trust, is a large self-managed investment trust headquartered in London, UK. The fund keeps its main focus on shares in publicly traded and privately held companies operating across diversified sectors. The company heavily invests in the public equity and currency markets worldwide. It tracks its portfolio performance against the RPI plus 3% and MSCI All Country World Index. RIT Capital employs a top-down approach to make its investments. The business operates internationally and is on the long-term growth of its capital oriented. The RIT Capital share price is listed on the London Stock Exchange and included in the FTSE 250 Index. Get updated info on the RCP share price at Capital.com.Latest shares articles

BNP Paribas stock forecast: Q2 earnings beat estimates
BNP Paribas is a French banking group whose recent developments include a Swift ledger transaction with HSBC for Siemens and continued focus on eurozone interest rates. Explore third-party BNP price targets and technical analysis. Past performance is not a reliable indicator of future results.
8 hours ago

Boeing stock forecast: FAA investigates Miami freighter crash
Boeing is a US aerospace manufacturer whose shares remain in focus after a 767-300 freighter crash in Miami prompted an FAA investigation. Explore third-party BA price targets and technical analysis. Past performance is not a reliable indicator of future results.
8 hours ago

CaixaBank stock forecast: BPI exits Angola market
CaixaBank is a Spanish bank whose Portuguese unit, Banco BPI, agreed to sell its 33.35% stake in Banco de Fomento de Angola for €388.5m. Explore third-party CABK price targets and technical analysis. Past performance is not a reliable indicator of future results.
9 hours ago

Valneva stock forecast: EMA validates Lyme vaccine application
Valneva is a French vaccine company listed on Euronext Paris. In August, the EMA validated the marketing-authorisation application for its Lyme disease vaccine candidate with Pfizer. Explore third-party VLA price targets. Past performance is not a reliable indicator of future results.
13 hours ago